Research programme: ATRN protein inhibitors - Atrin PharmaceuticalsAlternative Names: Ataxia telangiectasia and Rad3-related protein inhibitors - Atrin Pharmaceuticals; ATRN 502; ATRN 507; ATRN-119
Latest Information Update: 12 May 2016
At a glance
- Originator Atrin Pharmaceuticals
- Developer Atrin Pharmaceuticals; University of Pennsylvania
- Class Small molecules
- Mechanism of Action ATR protein inhibitors; P53 gene modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer